WILLIAM FRY LLP is delighted to have represented Polaris Partners and Elevage Medical Technologies on their lead investments in FIRE1’s recently-completed $120 million Series B fundraising, announced on 7 January 2025.

The William Fry team was led by Corporate Partner Mark Quealy, with support from Senior Associate Lucy McCurry.

This significant investment will support FIRE1’s pivotal clinical trials in the United States for its innovative remote monitoring solution, Norm, designed to improve outcomes for heart failure patients and reduce the burden on healthcare systems.